Cancer rates review - what did the review find?

The review found no unusual excess of cancers thought to be associated with dieldrin.

The primary source of data was the Australian Cancer Atlas, which includes comprehensive cancer incidence data for all of Australia by geographical area.

The notification of cancers to State and Territory cancer registers has been mandated for a number of years and the Atlas is considered to provide comprehensive coverage of all cancers diagnosed. This data can be used to analyse rates of cancer both across the country and in smaller localised areas.

If a concern about an unusually high number of cancers is raised, the data can be used to determine if a higher than expected number of cancers has been diagnosed in the area in previous years. 

The Chief Health Officer reviewed cancer incidence rates for total cancers, breast and liver cancer, and non-Hodgkin lymphoma, multiple myeloma, brain cancers and leukaemia.

Analysis of these data indicated there is no:

  • evidence of a higher rate of total cancers in any geographical areas of the Bellarine Peninsula than elsewhere in Australia
  • higher number of the specific cancers related to dieldrin (breast or liver) than would be expected (based on the average cancer rates in Australia)
  • higher number of cancers mentioned in the media (non-Hodgkin lymphoma, multiple myeloma, brain cancers and leukaemia) than would be expected (based on the average cancer rates in Australia).






Page last updated: Wednesday, 19 January 2022

Print